We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Blood Test Rules Out Future Dementia Risk

By LabMedica International staff writers
Posted on 07 Apr 2025

Previous studies have suggested that specific biomarkers, such as tau217, Neurofilament Light (NfL), and Glial Fibrillary Acidic Protein (GFAP), may be valuable for early dementia diagnosis. More...

However, most of these studies have involved individuals who sought medical care due to cognitive symptoms, such as memory difficulties. A larger, community-based study was needed to assess the predictive power of these biomarkers in the general population. Now, a new study published in Nature Medicine has explored the potential of these biomarkers to predict dementia, including Alzheimer's disease, up to ten years before an official diagnosis in cognitively healthy older adults living in the community.

This study, led by researchers at Karolinska Institutet (Stockholm, Sweden) and their collaborators, analyzed blood biomarkers in over 2,100 adults aged 60 and above, who were monitored over a period to track the development of dementia. Ten years later, 17% of participants had been diagnosed with dementia. The biomarkers tested in this study were found to be up to 83% accurate. However, the researchers observed that these biomarkers had low positive predictive values, meaning that elevated levels of the biomarkers alone could not reliably predict who would develop dementia in the next decade. As a result, the researchers recommend against using these biomarkers as widespread screening tools in the general population at this time. The study also suggested that combining the three most significant biomarkers—p-tau217 with NfL or GFAP—could enhance predictive accuracy.

“Our findings imply that if an individual has low levels of these biomarkers, their risk of developing dementia over the next decade is minimal," said Davide Vetrano, associate professor at the same department and the study's senior author. "This information could offer reassurance to individuals worried about their cognitive health, as it potentially rules out the future development of dementia. These biomarkers are promising, but they are currently not suitable as standalone screening tests to identify dementia risk in the general population.”


New
Gold Member
Hematology Analyzer
Medonic M32B
Portable Electronic Pipette
Mini 96
New
Sample Transportation System
Tempus1800 Necto
New
Autoimmune Liver Diseases Assay
Microblot-Array Liver Profile Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The test could streamline clinical decision-making by identifying ideal candidates for immunotherapy upfront (Xiao, Y. et al. Cancer Biology & Medicine July 2025, 20250038)

Blood Test Predicts Immunotherapy Efficacy in Triple-Negative Breast Cancer

Triple-negative breast cancer (TNBC) is an aggressive subtype lacking targeted therapies, making immunotherapy a promising yet unpredictable option. Current biomarkers such as PD-L1 expression or tumor... Read more

Technology

view channel
Image: The sensor can help diagnose diabetes and prediabetes on-site in a few minutes using just a breath sample (Photo courtesy of Larry Cheng/Penn State)

Graphene-Based Sensor Uses Breath Sample to Identify Diabetes and Prediabetes in Minutes

About 37 million U.S. adults live with diabetes, and one in five is unaware of their condition. Diagnosing diabetes often requires blood draws or lab visits, which are costly and inconvenient.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.